Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12768622 | 0.79 | TSHR (0.55) | TSHRALDH1A1TDP1CYP3A4ALOX15 | |
| SCHEMBL12262070 | 0.79 | TSHR (0.46) | TSHRALDH1A1TDP1CYP3A4ALOX15 | |
| SCHEMBL12574256 | 0.75 | PKM (0.49) | TSHRALDH1A1TDP1TP53HTT | |
| SCHEMBL4307844 | 0.71 | MAPT (0.42) | TSHRALDH1A1TDP1CYP3A4ALOX15 | |
| SCHEMBL3060349 | 0.70 | RAB9A (0.36) | TSHRALDH1A1TDP1L3MBTL1MAPT | |
| SCHEMBL28930047 | 0.69 | TSHR (0.45) | TSHRALDH1A1TDP1ALOX15L3MBTL1 | |
| SCHEMBL15047075 | 0.67 | TSHR (0.43) | TSHRALDH1A1TDP1CYP3A4ALOX15 | |
| SCHEMBL28196417 | 0.67 | TSHR (0.65) | TSHRALDH1A1ALOX15MAPT | |
| SCHEMBL5082936 | 0.67 | TSHR (0.43) | TSHRALDH1A1TDP1L3MBTL1MAPT | |
| SCHEMBL18701627 | 0.67 | TSHR (0.43) | TSHRALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115397819-B | PDE4 inhibitor compound and medical application thereof | 苏州隆博泰药业有限公司 | 2026-05-22 | — | — | CN | disclosed |
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-3789389-B1 | CRYSTALLINE FORM OF (S)-N-[5-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-4,6-DIOXO-5,6-DIHYDRO-4H-THIENO[3,4-C]PYRROLE-1-YL]ACETAMIDE | TIANJIN HEMAY PHARMACEUTICAL CO LTD (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-12227514-B2 | Crystal forms of thiophene derivatives | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2025-02-18 | — | — | US | disclosed |
| US-12180222-B2 | Crystal forms of thiophene derivatives | TIANJIN HEMAY PHARMACEUTICAL CO., LTD (CN) | 2024-12-31 | — | — | US | disclosed |
| EP-4335515-A2 | CRYSTAL FORMS OF (S)-N-[5-[1-(3-ETHOXY-4-METHOXYPHENYL)- 2-(METHYLSULFONYL)ETHYL]-4,6-DIOXO-5,6-DIHYDRO-4H-THIENO[3,4-C]PYRROLE-1 -YL]ACETAMIDE | Tianjin Hemay Pharmaceutical Co., Ltd. (CN) | 2024-03-13 | — | — | EP | disclosed |
| EP-3789387-B1 | CRYSTAL FORMS OF (S)-N-[5-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-4,6-DIOXO-5,6-DIHYDRO-4H-THIENO[3,4-C]PYRROLE-1-YL]ACETAMIDE | TIANJIN HEMAY PHARMACEUTICAL CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3789388-B1 | CRYSTAL FORM OF (S)-N-[5-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-4,6-DIOXO-5,6-DIHYDRO-4H-THIENO[3,4-C]PYRROLE-1-YL]ACETAMIDE | TIANJIN HEMAY PHARMACEUTICAL CO LTD (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-116947878-A | Crystalline forms of thiophene derivatives | 天津合美医药科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116854705-A | Crystalline forms of thiophene derivatives | 天津合美医药科技有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20120107269-A1 | THIOPHENE DERIVATIVES | Tianjin Hemay Biotech Co., Ltd (CN) | 2012-05-03 | — | — | US | disclosed |
| EP-2431371-A1 | THIOPHENE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2012-03-21 | — | — | EP | disclosed |
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-07-15 | — | — | US | disclosed |
| EP-2083011-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2009-07-29 | — | — | EP | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| CN-101186612-A | Pyrroline derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application | TIANJIN HEMEI BIOLOG TECHNOLOG (CN) | 2008-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180222-B2 | Crystal forms of thiophene derivatives | EIF4A3, PTP4A3, GTF3C4 | TSHR 1868/4885ALDH1A1 812/4885TDP1 1599/4885 |
| US-20120107269-A1 | THIOPHENE DERIVATIVES | TSHR, RB1, TAS2R7 | TSHR 1/4885ALDH1A1 950/4885TDP1 907/4885 |
| US-12227514-B2 | Crystal forms of thiophene derivatives | TST, SULT1E1, TPMT | TSHR 2066/4885ALDH1A1 796/4885TDP1 672/4885 |
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, NOS1 | TSHR 1213/4885ALDH1A1 1039/4885TDP1 2145/4885 |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, CD40 | TSHR 181/4885ALDH1A1 1581/4885TDP1 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.